Newsroom› Sectors
Sectors 06 August 2026

Healthcare & Life Sciences: demographic demand meets financing discipline

Care demand in Europe is inelastic and rising; the capital funding it has become considerably more selective. Where we see mandates clearing, and what owners of clinic groups, MedTech businesses and healthcare platforms should prepare for.

Demand is not the question — reimbursement is

Every investor committee understands the demographics. What they interrogate is the reimbursement path: who pays, under which code, at what margin, and how exposed that margin is to a single national tariff decision. In our healthcare mandates the fastest route to a competitive process is a reimbursement map that a non-specialist can follow, with the downside case already modelled at the tariff level rather than the revenue level.

Clinic and specialist care platforms: buy-and-build, done properly

Consolidation of fragmented specialist care continues across Germany, Switzerland, Iberia and the Nordics. The difference between a platform that attracts institutional capital and one that stalls is operational: clinician retention, a repeatable integration playbook and a real quality framework. Sponsors have been burned by roll-ups that bought revenue and inherited staffing risk, and they now underwrite the operating model first.

MedTech is being financed on evidence, not CE marks

Approval is table stakes. What gets funded is clinical and health-economic evidence strong enough to move a procurement committee, plus a commercial model that does not depend on one distributor per country. For European MedTech businesses scaling into the United States, the structuring question — subsidiary, partner or licence — increasingly determines valuation more than the technology.

Digital health has stopped selling software to hospitals

The successful digital health businesses in our pipeline sell an outcome inside a reimbursed pathway, not a licence to an IT department. That shift changes the buyer, the sales cycle and the capital requirement, and it makes working-capital planning a board-level topic rather than a finance one.

What we expect through 2028
Healthcare real estate and operator strategy converge further: capital increasingly wants the asset and the operating covenant underwritten as one package.
Cross-border consolidation of specialist care accelerates, with Iberian and Nordic assets drawing German, Swiss and Gulf capital.
Private credit takes a larger role in funding clinic expansion where equity would be prohibitively dilutive to founding clinicians.
Evidence-led MedTech and reimbursed digital pathways attract strategic buyers earlier, compressing the window between Series B and a trade process.

This commentary reflects the views of Avertis Group at the date of publication and is provided for information only. It is not investment, legal or tax advice, nor an offer or solicitation in respect of any security. Forward-looking statements are estimates and may not materialise.

Sector coverage Submit an Opportunity All news